In this study, we evaluated effect of tumor-antigen-primed MHC-haploidentical lymphocytes in a TC-1 (H-2b) murine lung cancer model. The haploidentical effector cells prepared from splenocytes stimulated with the tumor cell lysates pulsed-DCs from F1 (C57BL/6 × Balb/C, H-2bd) mice, or immunized from F1 mice vaccinated with inactivated tumor cells. Haploidentical lymphocytes immunized with TC-1 could specifically kill the TC-1 cells, as well as up-regulate the NK activity. The effector cells inactivated with Mitomycin C in vitro kept the killing capacity, and migrated to tumor tissue. Compared with the cells from non-inactivated, or the syngeneic mice, the cells from Mitomycin C inactivated mice with haploidentical showed enhanced tumor inhibition. The survival time increased in tumor bearing mice and some showed tumor free, which developed no tumor after rechallenged with TC-1.Th1 cytokines including IL-2, IFN-γwere significantly increased. These studies demonstrate that the tumor antigen immunized MHC-haploidentical lymphocytes could specificity target to the tumor and kill them. MHC-mismatched alloantigens could be an effective adjuvant to break the immune tolerance and to activate innate and adoptive immunity in the tumor bearing host. The infusion of the inactivated MHC-haploidentical lymphocytes immunized with tumor antigen could be a safe and effective adoptive immunotherapy against tumor.
- Copyright © 2013 by The American Association of Immunologists, Inc.